Avid Bioservices Inc (CDMO)

[freethemice]

I thought the whole point of a phase II trial was to look for efficacy and safety.
Usually these trials are not powered to show statistical significance and
I don't ever remember Peregrine stating that as a goal. Now we see that regardless
of ORR or PFS that the survival will greatly exceed the control arm in a randomized,
double-blinded, placebo controlled trial. In a phase III trial for second-line NSCLC
median overall survival is the end-point which is the most important and trumps everything else.
I would say bavi is looking pretty good right now as a candidate for a phase III trial
with survival as the end-point. What exactly is wrong with that?